DME Capital Management’s Immunovant IMVT Stock Holding History

DME Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.6M	Hold	93,520	–	–	0.09%	43
2026 Q1	$2.32M	Buy	+93,520	New	+$2.42M	0.07%	41

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DME Capital Management's IMVT Position: Q2 2026 in Review

DME Capital Management held its Immunovant (IMVT) position steady in Q2 2026 at 93,520 shares worth $3.6M. The position accounts for 0.09% of the portfolio, ranked #43.

DME Capital Management first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

DME Capital Management held 93,520 shares of Immunovant worth $3.6M as of Q2 2026.
DME Capital Management left its Immunovant share count unchanged in Q2 2026.
Immunovant made up 0.09% of DME Capital Management's portfolio in Q2 2026, its #43 holding.
DME Capital Management first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on DME Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.